Aerovate Therapeutics, Inc. (AVTE)
USD 2.53
(-1.17%)
USD 2.53
(-1.17%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -56.77 Million | -39.12 Million | -27.39 Million | -7.85 Million | -2.78 Million |
| Net Income | -75.52 Million | -51.51 Million | -22.96 Million | -9.61 Million | -3.33 Million |
| Depreciation & Amortization | 96 Thousand | 68 Thousand | 15 Thousand | 1000.00 | - |
| Deferred income taxes | 164 Thousand | - | - | - | - |
| Stock-based compensation | 11.9 Million | 5.47 Million | 2.04 Million | 58 Thousand | - |
| Change in working capital | 9.79 Million | 7.75 Million | -6.51 Million | 974 Thousand | 549 Thousand |
| Other non-cash items | -3.22 Million | -910 Thousand | 16 Thousand | 719 Thousand | -436 Thousand |
| Investing Cash Flow | 11.87 Million | 6.92 Million | -113.43 Million | - | - |
| Investments in PPE | -142 Thousand | -195 Thousand | -181 Thousand | - | - |
| Acquisitions | -12.01 Thousand | -7121.00 | - | - | - |
| Investment purchases | -123.98 Million | -147.62 Million | -113.25 Million | - | - |
| Sales/Maturities of investments | 136 Million | 154.74 Million | - | - | - |
| Other Investing Activities | 12.01 Thousand | 7121.00 | -113.25 Thousand | - | - |
| Financing Cash Flow | 45.99 Million | 396 Thousand | 190.45 Million | 8.91 Million | 2.5 Million |
| Debt repayment | - | - | - | -2.5 Million | -2.5 Million |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | 45.99 Million | 150 Thousand | 126.94 Million | 6.41 Million | - |
| Other Financing Activities | -234 Thousand | 246 Thousand | 63.51 Million | 5 Million | 5 Million |
| Accounts receivables | - | - | - | - | - |
| Accounts payables | -164 Thousand | 1.36 Million | 609 Thousand | 37 Thousand | 436 Thousand |
| Inventory | - | - | - | - | - |
| Other working capital | 9.96 Million | 6.38 Million | -7.11 Million | 937 Thousand | 113 Thousand |
| Cash at beginning of period | 22.39 Million | 54.19 Million | 4.57 Million | 3.51 Million | 3.79 Million |
| Cash at end of period | 23.49 Million | 22.39 Million | 54.19 Million | 4.57 Million | 3.51 Million |
| Capital Expenditure | -142 Thousand | -195 Thousand | -181 Thousand | - | - |
| Effect of forex changes on cash | - | - | - | - | - |
| Net cash flow / Change in cash | 1.09 Million | -31.8 Million | 49.62 Million | 1.05 Million | -281 Thousand |
| Free Cash Flow | -56.92 Million | -39.31 Million | -27.58 Million | -7.85 Million | -2.78 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -24.77 Million | -23.18 Million | -75.52 Million | -20.41 Million | -19.56 Million | -19.02 Million |
| Depreciation & Amortization | 28 Thousand | 28 Thousand | 96 Thousand | 28 Thousand | 25 Thousand | 22 Thousand |
| Deferred income taxes | - | - | 164 Thousand | -4.35 Million | - | - |
| Stock-based compensation | 3.86 Million | 4.2 Million | 11.9 Million | 3.25 Million | 3.23 Million | 3.03 Million |
| Change in working capital | 1.14 Million | -3.95 Million | 9.79 Million | 3.27 Million | 1.49 Million | 1.66 Million |
| Other non-cash items | 2.28 Million | 2.66 Million | -3.22 Million | 3.41 Million | -808 Thousand | -639 Thousand |
| Investing Cash Flow | 18 Million | 8.83 Million | 11.87 Million | 5.64 Million | -13.13 Million | 3.98 Million |
| Investments in PPE | - | - | -142 Thousand | -64 Thousand | -32 Thousand | -30 Thousand |
| Acquisitions | - | - | -12.01 Thousand | -5712.00 | 13.09 Thousand | -4013.00 |
| Investment purchases | - | -14.75 Million | -123.98 Million | -27.78 Million | -47.84 Million | -32.73 Million |
| Sales/Maturities of investments | 18 Million | 23.58 Million | 136 Million | 33.5 Million | 34.75 Million | 36.75 Million |
| Other Investing Activities | 18 Million | 8.83 Million | 12.01 Thousand | 5712.00 | -13.09 Thousand | 4013.00 |
| Financing Cash Flow | 24.38 Million | 471 Thousand | 45.99 Million | 463 Thousand | 20 Thousand | 45.29 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 24.38 Million | 471 Thousand | 45.99 Million | 463 Thousand | 20 Thousand | 45.29 Million |
| Other Financing Activities | -74 Thousand | -233 Thousand | -234 Thousand | 463.00 | -75 Thousand | 45.29 Thousand |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 948 Thousand | 835 Thousand | -164 Thousand | -1.04 Million | -2.01 Million | 773 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 193 Thousand | -4.79 Million | 9.96 Million | 4.31 Million | 3.51 Million | 892 Thousand |
| Cash at beginning of period | 9.12 Million | 23.49 Million | 22.39 Million | 32.18 Million | 60.9 Million | 26.57 Million |
| Cash at end of period | 31.06 Million | 9.12 Million | 23.49 Million | 23.49 Million | 32.18 Million | 60.9 Million |
| Capital Expenditure | - | - | -142 Thousand | -64 Thousand | -32 Thousand | -30 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 21.94 Million | -14.36 Million | 1.09 Million | -8.68 Million | -28.72 Million | 34.33 Million |
| Free Cash Flow | -20.43 Million | -23.67 Million | -56.92 Million | -14.86 Million | -15.64 Million | -14.97 Million |
338100
4099
ONEX
SRECR
ADM
0756